BiomX was granted orphan status for a treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with Cystic Fibrosis, according to a post to the FDA’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHGE:
- BiomX files $150M mixed securities shelf
- BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX announces results from Part 2 of the Phase 1b/2a trial of BX004
- BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
- PHGE Upcoming Earnings Report: What to Expect?
